John Canepa, Chief Financial Officer

John was a member of the team that acquired Asterand Bioscience Inc. in the fall of 2012 and leads the Company’s business activities. Mr. Canepa began his professional career spending 23 years in the Boston office of Arthur Andersen where he was an audit partner working primarily with technology-based companies. He was also in charge of the firm’s worldwide life science practice. John left Anderson in 2001 and entered the entrepreneurial world.  He has been CFO of Winphoria Networks, a telecommunications software company acquired by Motorola in 2003, and CEO of U.S. Genomics Inc. and PathoGenetix Inc. John has a BA from Denison University and an MBA from Michigan State University. Furthermore, he is on the board of directors of Harvard Apparatus Regenerative Technology and Chairman of the board of trustees of Mount Auburn Hospital.


Peter Ferrigno, Chief Commercial Officer

Peter joined Asterand Bioscience Inc. as Chief Commercial Officer in March 2013. His prior experience included 33 years working at Becton Dickinson (BD), a fortune 500 Global Medical Device Company.  Over his BD career, Peter held senior level positions as General Manager, VP Sales and Marketing, VP Business Development, and VP Distribution Management. Peter worked across several BD businesses focused in clinical research, life sciences, pharmaceutical and diabetes care. His scope of responsibilities covered P&L, world-wide business development, channel management, and business strategy. Peter earned a Bachelor of Science degree in business economics/biology from Niagara University. In addition, he currently serves on the Board of Marist College School of Management and is an active contributing member of the Massachusetts Biotech council.


Amanda Woodrooffe, PhD, Vice President & General Manager, UK Operations

Amanda joined Asterand Bioscience Inc. in 2001 (then known as Pharmagene) and was appointed General Manager UK in 2010 with responsibility for leading the UK services business. Prior to her current role, Amanda was responsible for progressing Asterand Bioscience’s corporate development activities through researching, sourcing and prioritizing scientific opportunities and leading scientific diligence for M&A. Previously, Amanda was a Scientific Department Head responsible for delivery of client projects and for leading DMPK activities for Pharmagene’s internal drug discovery programs. Prior to joining Pharmagene, Amanda worked for 7 years at various Glaxo companies, where her research focused on the use of human in vitro approaches.  Amanda holds PhD in in vitro drug-interactions from the University of Cambridge.


Shannon Richey, Vice President & General Manager, Detroit Operations

Shannon joined the Company in 2007 working primarily in Marketing and Commercial Operations.  More recently,  Shannon led Asterand Bioscience’s custom procurement business segment until 2015 when she was appointed to oversee the entire Detroit-based laboratory operations. Before joining Asterand Bioscience, Shannon held managerial and executive level positions within the life science and pharmaceutical industry. She has been a Director of Sales and Marketing at Assay Designs (Enzo Life Sciences), and EVP of Marketing at Genomic Solutions, where she was a member of the team that guided the Company through its IPO in 2000. She has also held managerial positions at Immuno US (Baxter Hyland) and Schering Plough. Shannon earned a BA from Wayne State University and an MBA from Cornell University.


Tony Brown, PhD, Vice President, Scientific and Corporate Development

Tony has been with Asterand Bioscience for 16 years. Prior to taking up his current position, he held a number of senior positions within the company including General Manager for the UK Services business and General Manager for the Detroit-based tissue products business. In addition, he was appointed VP, Strategic Alliances, with responsibility for securing and managing the Company’s human tissue supply collaborations. Tony began his career teaching physiology at Nottingham University Medical School in the UK after obtaining degrees in engineering, bioengineering and a PhD in physiology. He subsequently joined SmithKline Beecham in 1988, where he headed the receptor pharmacology group within neurosciences research and led several drug discovery projects and drug screening programs.  Tony joined Pharmagene (now Asterand Bioscience) in 1998. Tony has published on the pharmacology and biochemistry of ion and neurotransmitter transport and on the use of human tissues for research in drug discovery and development.


Michael Button, Sr. Director of Supply Chain and Strategic Development

Michael has been with Asterand Bioscience since 2009 and is responsible for global purchasing, inventory control, and supplier management. He also leads the Company’s government initiatives with both The Cancer Genome Atlas Program and The Clinical Proteomic Tumor Analysis Consortium. Michael began his career at Dow Chemical where he worked in various supply chain capacities.  After Dow, Michael spent two years at the global strategy firm, Bain & Company, working on strategic growth and profitability initiatives Later on, Michael left Bain to join ThyssenKrupp Materials NA (TKMNA) where he held multiple executive level positions spanning operations management, supply chain optimization, and mergers & acquisitions. Micheal joined Asterand Bioscience to enter the entrepreneurial world and to work in a new and emerging industry. Michael holds a BS from Purdue University and a MBA with Distinction from The Harvard Business School.


Cathie G. Miller, PhD, Director of Product Marketing

Cathie joined Asterand Bioscience Inc. in 2015 and is responsible for global product management and marketing activities. Before joining Asterand Bioscience, Inc., Cathie was the Global Product Manager for the Biobanking, Chromatography and various other product lines at WHEATON and Director of the Human Biological Data Interchange at the National Disease Research Interchange. Her research career extended for 20 years across immunology, virology and cancer therapeutics. Cathie holds a PhD in Microbiology and Immunology from the University of Louisville and completed her post-doctoral studies at the Wistar Institute and the University of Pennsylvania. She was also Director of the Gayle Helparin-Kahn Laboratory of Viral Onco-Therapeutics at Henry Ford Health System.


Pamela Filipowicz, Director Human Resources

Pam has been a part of the Asterand Bioscience team since 2009 and is responsible for the global human resources function. She has over 16 years of human resources experience including recruiting, performance management, career development, employee relations, benefits, compensation, employee engagement, payroll, and organizational change. Prior to joining Asterand Bioscience, Pam worked at PPOM, a Michigan based health network, and Aetna, Inc., one of the largest health networks in America. She supported over 600 employees at multiple sites across the US  during her position at Aetna, Inc.

Pam gained significant expertise in benefits and employee relations, and was key to managing the business’s HR needs through several mergers and acquisitions while at these two organizations. Pam graduated with honors from Oakland University with a BA in history, and a minor in labor and employment studies. She is certified as a Senior Professional in Human Resources (SPHR), and is a member of the Society for Human Resource Management (SHRM).


For further information, contact us at

Ian Ratcliffe

Mr. Ratcliffe is the Chairman and CEO of Enzymatics, a leading producer of reagents, kits, and assays that enable customers worldwide to transform patient diagnosis, treatment, and life science research. Ian was a founder, CEO and a director of Stemgent Inc. Stemgent Inc. is a life science company focused on the development and sale of novel consumable reagents, and a leading global provider of high quality, human tissue and human tissue-based research solutions to drug discovery scientists.

Prior to Stemgent, he served as President of Upstate, a leading provider of cell signaling research products and services. In this position Mr. Ratcliffe was instrumental in facilitating the acquisition of Upstate by Serologicals, Corp. and was subsequently retained as President of the Upstate division. Ian earned a degree in Chemical Engineering from University of Surrey and has an MBA from the Darden Graduate School of Business Administration at the University of Virginia. He is a director of Global Cell Solutions LLC (Charlottesville), a biotech company commercializing proprietary 3D cell culture technology.


Ralph E. (Chris) Christoffersen, PhD

Chris Christoffersen joined Morgenthaler Ventures in 2001. Based in Boulder, Colorado, he focuses on biotechnology investments. Previously, Chris was the President and CEO of Ribozyme Pharmaceuticals, Inc., a Morgenthaler portfolio biotechnology company with a mission to commercialize the Nobel Prize-winning discovery of ribozymes for use as human therapeutics. He currently serves on seven corporate boards. Chris has been involved with a number of other successful ventures in the biotechnology field including Threshold Pharmaceuticals, Avidia Biosciences, and Morphotek, Inc. He has also served as the Senior Vice President of Research at SmithKline Beecham, Vice President of Discovery Research at The Upjohn Company, and President of Colorado State University.

Chris received an honorary doctor of law degree from Cornell College in 1983, the “Outstanding Researcher of the Year” Award from the International Society of Quantum Biology in 1981, the “W.E. Upjohn Award” for contributions in biotechnology in 1988, and a Lifetime Achievement Award in 2003 from the Colorado Biosciences Association. Doctor Christoffersen received his BS in chemistry and mathematics and an Honorary JD from Cornell College. Moreover, he received his PhD in chemistry from Indiana University.


Augustine Lawlor

Augustine Lawlor is the Managing Partner of HealthCare Ventures. He was chief operating officer of LeukoSite, Inc., a HealthCare Ventures III, IV, and V company prior to joining HealthCare Ventures in 2000. Before joining LeukoSite, Mr. Lawlor was chief financial officer and vice president of corporate development for Alpha-Beta Technology. He held similar positions at BioSurface Technology and Armstrong Pharmaceuticals. Mr. Lawlor has also served as a management consultant with KPMG Peat Marwick. Mr. Lawlor received his Master’s degree in public and private management from Yale University.


Harold R. Werner

Hal Werner is a Managing Director and Co-founder of HealthCare Ventures. Prior to the formation of HealthCare Ventures, Mr. Werner served as director of new ventures for Johnson & Johnson Development Corporation. Mr. Werner also has served as senior vice president of Robert S. First, Inc., an international health care consulting firm. Mr. Werner received his MBA degree from Harvard University.


For further information, contact us at